TG Therapeutics lifts 2026 revenue outlook to about $1 billion after Q3
TG Therapeutics reported Q3 2026 revenue of $259.9 million, including $232.6 million in US BRIUMVI sales, and raised full-year guidance from about $950 million.
Tag
guidance
Stories tagged guidance.